JP6431478B2 - Ｂ型肝炎ウイルスのｃｃｃｄｎａの転写の調節 - Google Patents
Ｂ型肝炎ウイルスのｃｃｃｄｎａの転写の調節 Download PDFInfo
- Publication number
- JP6431478B2 JP6431478B2 JP2015515256A JP2015515256A JP6431478B2 JP 6431478 B2 JP6431478 B2 JP 6431478B2 JP 2015515256 A JP2015515256 A JP 2015515256A JP 2015515256 A JP2015515256 A JP 2015515256A JP 6431478 B2 JP6431478 B2 JP 6431478B2
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- cccdna
- hepatitis
- alkyl
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *C(***C(NC(*)C(NC1Cc2c[n](*)c3c2cccc3)=O)=O)NC1=O Chemical compound *C(***C(NC(*)C(NC1Cc2c[n](*)c3c2cccc3)=O)=O)NC1=O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
- C07K5/123—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
- C07K5/126—Tetrapeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261654374P | 2012-06-01 | 2012-06-01 | |
| US61/654,374 | 2012-06-01 | ||
| PCT/US2013/043691 WO2013181584A2 (en) | 2012-06-01 | 2013-05-31 | Modulation of hepatitis b virus cccdna transcription |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015518055A JP2015518055A (ja) | 2015-06-25 |
| JP2015518055A5 JP2015518055A5 (enExample) | 2016-07-07 |
| JP6431478B2 true JP6431478B2 (ja) | 2018-11-28 |
Family
ID=49674087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015515256A Expired - Fee Related JP6431478B2 (ja) | 2012-06-01 | 2013-05-31 | Ｂ型肝炎ウイルスのｃｃｃｄｎａの転写の調節 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9623071B2 (enExample) |
| EP (1) | EP2854832A4 (enExample) |
| JP (1) | JP6431478B2 (enExample) |
| KR (1) | KR101945578B1 (enExample) |
| CN (1) | CN104507488A (enExample) |
| AU (2) | AU2013267209B2 (enExample) |
| BR (1) | BR112014029697A2 (enExample) |
| CA (1) | CA2874828A1 (enExample) |
| HK (1) | HK1208823A1 (enExample) |
| IL (1) | IL235912A0 (enExample) |
| PH (1) | PH12014502659A1 (enExample) |
| SG (1) | SG11201407970VA (enExample) |
| WO (1) | WO2013181584A2 (enExample) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101939710B1 (ko) | 2011-12-21 | 2019-01-17 | 노비라 테라퓨틱스, 인코포레이티드 | B형 간염의 항바이러스성 제제 |
| UY34993A (es) | 2012-08-28 | 2014-02-28 | Janssen R & D Ireland | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b |
| RU2015121940A (ru) * | 2012-11-09 | 2016-12-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Альтернативные применения эффекторов сборки вируса гепатита в (hbv) |
| IL239317B (en) | 2012-12-12 | 2022-07-01 | Broad Inst Inc | Providing, engineering and optimizing systems, methods and compositions for sequence manipulation and therapeutic applications |
| EP3434776A1 (en) | 2012-12-12 | 2019-01-30 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
| WO2014093701A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| WO2014131847A1 (en) | 2013-02-28 | 2014-09-04 | Janssen R&D Ireland | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
| JP6419155B2 (ja) | 2013-04-03 | 2018-11-07 | ヤンセン・サイエンシズ・アイルランド・ユーシー | Ｎ−フェニル−カルボキサミド誘導体およびｂ型肝炎を治療するための医薬品としてのその使用 |
| JO3583B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| EP3725885A1 (en) | 2013-06-17 | 2020-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof |
| CN105793425B (zh) | 2013-06-17 | 2021-10-26 | 布罗德研究所有限公司 | 使用病毒组分靶向障碍和疾病的crispr-cas系统和组合物的递送、用途和治疗应用 |
| JP6665088B2 (ja) | 2013-06-17 | 2020-03-13 | ザ・ブロード・インスティテュート・インコーポレイテッド | 配列操作のための最適化されたＣＲＩＳＰＲ−Ｃａｓ二重ニッカーゼ系、方法および組成物 |
| WO2014204724A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
| MX2015017312A (es) | 2013-06-17 | 2017-04-10 | Broad Inst Inc | Suministro y uso de composiciones, vectores y sistemas crispr-cas para la modificación dirigida y terapia hepáticas. |
| NO3024819T3 (enExample) | 2013-07-25 | 2018-07-21 | ||
| MX368158B (es) | 2013-10-23 | 2019-09-20 | Janssen Sciences Ireland Uc | Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
| BR112016013547A2 (pt) | 2013-12-12 | 2017-10-03 | Broad Inst Inc | Composições e métodos de uso de sistemas crispr-cas em distúrbios de repetições de nucleotídeos |
| WO2015089473A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation |
| WO2015089486A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems |
| RU2016128077A (ru) | 2013-12-12 | 2018-12-06 | Те Брод Инститьют Инк. | Доставка, применение и применения в терапии систем и композиций crispr-cas для лечения обусловленных hbv и вирусных заболеваний и нарушений |
| CN111206032B (zh) | 2013-12-12 | 2024-07-19 | 布罗德研究所有限公司 | 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用 |
| WO2015089364A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Crystal structure of a crispr-cas system, and uses thereof |
| US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| WO2015120178A1 (en) | 2014-02-05 | 2015-08-13 | Novira Therapeutics, Inc. | Combination therapy for treatment of hbv infections |
| DK3102572T3 (en) | 2014-02-06 | 2019-02-04 | Janssen Sciences Ireland Uc | SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B |
| US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
| RU2711750C2 (ru) * | 2014-06-20 | 2020-01-21 | Дрексель Юнивёрсити | Меченый антиген е гепаднавируса и его применение в скрининге противовирусных веществ |
| EP3230451B1 (en) | 2014-12-12 | 2021-04-07 | The Broad Institute, Inc. | Protected guide rnas (pgrnas) |
| CA2970370A1 (en) | 2014-12-24 | 2016-06-30 | Massachusetts Institute Of Technology | Crispr having or associated with destabilization domains |
| HK1247147A1 (zh) | 2015-03-19 | 2018-09-21 | 诺维拉治疗公司 | 氮杂环辛烷和氮杂环壬烷衍生物以及治疗乙型肝炎感染的方法 |
| US10442788B2 (en) | 2015-04-01 | 2019-10-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
| IL293323B2 (en) | 2015-06-18 | 2024-01-01 | Massachusetts Inst Technology | Crispr enzyme mutations reducing off-target effects |
| WO2016205759A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| US10179131B2 (en) | 2015-07-13 | 2019-01-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US10301255B2 (en) | 2015-07-22 | 2019-05-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2017015451A1 (en) * | 2015-07-22 | 2017-01-26 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| KR101771309B1 (ko) * | 2015-07-24 | 2017-08-24 | 재단법인 목암생명과학연구소 | B형 간염 바이러스의 ｃｃｃＤＮＡ 형성 억제용 약학 조성물 |
| CN108430971A (zh) | 2015-09-29 | 2018-08-21 | 诺维拉治疗公司 | 乙型肝炎抗病毒剂的晶体形式 |
| US10280175B2 (en) | 2016-02-02 | 2019-05-07 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| KR102398439B1 (ko) | 2016-03-07 | 2022-05-16 | 이난타 파마슈티칼스, 인코포레이티드 | B형 간염 항바이러스제 |
| KR20180129943A (ko) | 2016-04-15 | 2018-12-05 | 노비라 테라퓨틱스, 인코포레이티드 | 캡시드 조립 억제제를 포함하는 배합물 및 방법 |
| SG11201810834WA (en) | 2016-06-10 | 2018-12-28 | Enanta Pharm Inc | Hepatitis b antiviral agents |
| JP7373991B2 (ja) | 2016-07-15 | 2023-11-06 | ビラクタ セラピューティクス，インク． | 免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤 |
| RU2019120163A (ru) | 2016-12-13 | 2021-01-15 | Ам Сиенсес Инк | Фармацевтическая композиция для предупреждения или лечения гепатита B |
| EA202090514A1 (ru) | 2017-08-28 | 2020-06-24 | Энанта Фармасьютикалс, Инк. | Противовирусное средство против гепатита в |
| CN112105359B (zh) * | 2017-12-04 | 2023-12-01 | 豪夫迈·罗氏有限公司 | 作为cccDNA抑制剂用于治疗乙型肝炎病毒(HBV)感染的吡咯并[2,3-b]吡嗪化合物 |
| TW201927789A (zh) | 2017-12-06 | 2019-07-16 | 美商因那塔製藥公司 | B型肝炎抗病毒試劑 |
| US10723733B2 (en) | 2017-12-06 | 2020-07-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2019143902A2 (en) | 2018-01-22 | 2019-07-25 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| JP2021515769A (ja) | 2018-03-14 | 2021-06-24 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | カプシド集合調節剤の投薬レジメン |
| US10729688B2 (en) | 2018-03-29 | 2020-08-04 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2019240504A1 (en) * | 2018-06-12 | 2019-12-19 | Am Sciences Co., Ltd. | Modified oligonucleotides for inhibition of target gene expression |
| KR102273071B1 (ko) * | 2018-06-12 | 2021-07-05 | 주식회사 에이엠사이언스 | B형 간염 예방 또는 치료용 조성물 |
| CA3113235A1 (en) | 2018-09-21 | 2020-03-26 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| US20210387996A1 (en) * | 2018-10-24 | 2021-12-16 | Hoffmann-La Roche Inc. | Tricyclic compounds for the treatment and prophylaxis of hepatitis b virus disease |
| IL283190B2 (en) | 2018-11-21 | 2025-08-01 | Enanta Pharm Inc | Functionalized heterocycles as antiviral agents |
| US11096931B2 (en) | 2019-02-22 | 2021-08-24 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
| US11491148B2 (en) | 2019-05-06 | 2022-11-08 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
| MX2021014639A (es) | 2019-05-31 | 2022-04-06 | Viracta Subsidiary Inc | Metodos para tratar canceres asociados con virus con inhibidores de la histona deacetilasa. |
| US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| WO2021007488A1 (en) | 2019-07-11 | 2021-01-14 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| EP4037706A4 (en) * | 2019-10-02 | 2023-09-13 | University of Washington | Compositions and methods for treatment of hepatitis b virus infection |
| US11802125B2 (en) | 2020-03-16 | 2023-10-31 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| EP4200419A2 (en) * | 2020-08-21 | 2023-06-28 | F. Hoffmann-La Roche AG | Use of a1cf inhibitors for treating hepatitis b virus infection |
| CN112274516B (zh) * | 2020-10-26 | 2022-08-05 | 中山大学附属第三医院 | 一种新型含碘抗病毒药物 |
| IT202100005054A1 (it) * | 2021-03-04 | 2022-09-04 | Azienda Ospedaliero Univ Di Parma | Composto farmaceutico per l’uso in un trattamento terapeutico dell’infezione cronica da hbv e metodo per l’identificazione di linfociti esauriti |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002051846A1 (en) | 2000-12-22 | 2002-07-04 | Zee, Ok Pyo | Apicidin-derivatives, their synthetic methods, and antitumor compositions containing the same |
| US20100009970A1 (en) * | 2008-03-19 | 2010-01-14 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
| US20110086869A1 (en) | 2009-09-24 | 2011-04-14 | The Trustees Of Boston University | Methods for treating viral disorders |
| US20110245154A1 (en) * | 2010-03-11 | 2011-10-06 | Hemaquest Pharmaceuticals, Inc. | Methods and Compositions for Treating Viral or Virally-Induced Conditions |
-
2013
- 2013-05-31 JP JP2015515256A patent/JP6431478B2/ja not_active Expired - Fee Related
- 2013-05-31 CA CA2874828A patent/CA2874828A1/en not_active Abandoned
- 2013-05-31 WO PCT/US2013/043691 patent/WO2013181584A2/en not_active Ceased
- 2013-05-31 BR BR112014029697A patent/BR112014029697A2/pt not_active Application Discontinuation
- 2013-05-31 EP EP13797412.7A patent/EP2854832A4/en not_active Withdrawn
- 2013-05-31 SG SG11201407970VA patent/SG11201407970VA/en unknown
- 2013-05-31 HK HK15109632.8A patent/HK1208823A1/xx unknown
- 2013-05-31 CN CN201380035280.3A patent/CN104507488A/zh active Pending
- 2013-05-31 AU AU2013267209A patent/AU2013267209B2/en not_active Ceased
- 2013-05-31 KR KR1020147036640A patent/KR101945578B1/ko not_active Expired - Fee Related
- 2013-05-31 US US14/435,675 patent/US9623071B2/en not_active Expired - Fee Related
-
2014
- 2014-11-26 IL IL235912A patent/IL235912A0/en unknown
- 2014-11-28 PH PH12014502659A patent/PH12014502659A1/en unknown
-
2017
- 2017-04-10 US US15/483,711 patent/US10143720B2/en not_active Expired - Fee Related
- 2017-04-21 AU AU2017202675A patent/AU2017202675A1/en not_active Abandoned
-
2018
- 2018-08-28 US US16/115,298 patent/US20180369323A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014029697A2 (pt) | 2017-08-08 |
| WO2013181584A3 (en) | 2014-02-13 |
| AU2017202675A1 (en) | 2017-05-11 |
| CN104507488A (zh) | 2015-04-08 |
| KR101945578B1 (ko) | 2019-02-07 |
| US9623071B2 (en) | 2017-04-18 |
| US20150265672A1 (en) | 2015-09-24 |
| PH12014502659A1 (en) | 2015-01-21 |
| CA2874828A1 (en) | 2013-12-05 |
| IL235912A0 (en) | 2015-01-29 |
| HK1208823A1 (en) | 2016-03-18 |
| JP2015518055A (ja) | 2015-06-25 |
| US20170296619A1 (en) | 2017-10-19 |
| EP2854832A4 (en) | 2016-06-08 |
| AU2013267209A1 (en) | 2014-12-18 |
| EP2854832A2 (en) | 2015-04-08 |
| US10143720B2 (en) | 2018-12-04 |
| US20180369323A1 (en) | 2018-12-27 |
| KR20150022911A (ko) | 2015-03-04 |
| AU2013267209B2 (en) | 2017-02-02 |
| WO2013181584A2 (en) | 2013-12-05 |
| SG11201407970VA (en) | 2014-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10143720B2 (en) | Modulation of hepatitis B virus cccDNA transcription | |
| JP6159814B2 (ja) | Ｍａｌｔ１の低分子阻害剤 | |
| JP5598775B2 (ja) | 癌の介入治療および根絶のためのｉｔｅとその類似体を含む医薬組成物 | |
| TW201121958A (en) | Methods of treating hepatitis C virus with oxoacetamide compounds | |
| BR112020013247A2 (pt) | amidas heterocíclicas como inibidores de quinase | |
| AU2021258431A1 (en) | Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof | |
| US20180016243A1 (en) | Human helicase ddx3 inhibitors as therapeutic agents | |
| JP2020203947A (ja) | Ｎｓ５ａ、ｎｓ５ｂまたはｎｓ３阻害剤を使用する、ｂ型肝炎ウイルス感染症を処置するための方法 | |
| Bissegger et al. | Rapid, potent, and persistent covalent chemical probes to deconvolute PI3Kα signaling | |
| EP4096633A1 (en) | Dosages and methods for treating pulmonary arterial hypertension with rodatristat | |
| WO2013059548A9 (en) | Compositions and methods for treating cancer using jak2 inhibitor | |
| JP2014208611A (ja) | Ｉｌ−２産生抑制 | |
| TW202425969A (zh) | 吲唑吡啶酮化合物及其用途 | |
| Khojasteh et al. | Drug Properties | |
| WO2022251386A1 (en) | Modulating expression level of a gene encoding a cytochrome p450 protein by treating a human subject with a nitroxide | |
| CN122003240A (zh) | 组合疗法和其用途 | |
| US20190374485A1 (en) | Compositions and methods for treating hepatocellular carcinoma | |
| HK40006039A (en) | Combination of ledipasvir and sofosbuvir for use in the treatment of hepatitis b virus infections in humans | |
| HK40006039B (en) | Combination of ledipasvir and sofosbuvir for use in the treatment of hepatitis b virus infections in humans | |
| HK1116090A (en) | Thiazole compounds and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160518 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160518 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170418 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170718 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170919 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170927 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171129 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180228 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180305 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180612 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180912 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181004 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181102 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6431478 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |